Atherosclerosis, which underlies life-threatening cardiovascular disorders such as myocardial infarction and stroke 1 , is initiated by passage of low-density lipoprotein (LDL) cholesterol into the artery wall and its engulfment by macrophages, which leads to foam cell formation and lesion development 2, 3 . It is unclear how circulating LDL enters the artery wall to instigate atherosclerosis. Here we show in mice that scavenger receptor class B type 1 (SR-B1) in endothelial cells mediates the delivery of LDL into arteries and its accumulation by artery wall macrophages, thereby promoting atherosclerosis. LDL particles are colocalized with SR-B1 in endothelial cell intracellular vesicles in vivo, and transcytosis of LDL across endothelial monolayers requires its direct binding to SR-B1 and an eight-amino-acid cytoplasmic domain of the receptor that recruits the guanine nucleotide exchange factor dedicator of cytokinesis 4 (DOCK4) 4 . DOCK4 promotes internalization of SR-B1 and transport of LDL by coupling the binding of LDL to SR-B1 with activation of RAC1. The expression of SR-B1 and DOCK4 is increased in atherosclerosis-prone regions of the mouse aorta before lesion formation, and in human atherosclerotic arteries when compared with normal arteries. These findings challenge the longheld concept that atherogenesis involves passive movement of LDL across a compromised endothelial barrier. Interventions that inhibit the endothelial delivery of LDL into artery walls may represent a new therapeutic category in the battle against cardiovascular disease.
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In atherosclerosis, the balance of actions of lipoprotein particles governs the severity of the disorder and the likelihood that clinical cardiovascular events will occur. Whereas LDL that enters the artery wall is the critical driver of atherogenesis, via binding to SR-B1 in hepatocytes, high-density lipoprotein (HDL) particles mediate reverse cholesterol transport (RCT) to the liver for biliary disposal and are thereby anti-atherogenic 5 . In addition, in endothelial cells HDL acts via SR-B1 and its adaptor PDZK1 to stimulate endothelial NO synthase (eNOS) 6 , endothelial repair and anti-inflammatory processes that may also be atheroprotective 7 . To determine how SR-B1 in the endothelium affects atherosclerosis, we generated mice lacking SR-B1 selectively in the endothelium (SR-B1 . In all models tested, the endothelial deletion of SR-B1 that yielded atheroprotection did not alter circulating total cholesterol, triglyceride or HDL levels, or lipoprotein profile ( Fig. 1j -o) had no effect on lesion severity (Extended Data Fig. 2o-s) . Thus, in marked contrast to its role in hepatocytes, SR-B1 in the endothelium promotes atherosclerosis in the absence of an effect on circulating lipids or vascular inflammation and independent of processes governed by PDZK1.
As SR-B1 is a receptor for both HDL and LDL 9 , and in cultured endothelial cells SR-B1 promotes LDL transcytosis 10 , we tested the hypothesis that endothelial SR-B1 influences atherosclerosis by regulating LDL-related processes in the artery wall. Transfer of DiI-labelled human native LDL (nLDL) into the aorta was visualized in vivo by confocal fluorescence microscopy. Following intravenous injection, far less DiI-nLDL entered the aorta of SR-B1 ΔEC mice than SR-B1 fl/fl controls ( Fig. 1j-l) . Because circulating oxidized LDL (oxLDL) may also contribute to atherogenesis 11, 12 , we also visualized transfer of DiI-labelled human oxLDL, and it was similarly diminished in SR-B1 ΔEC mice (Extended Data Fig. 6a -c, Supplementary Videos 1 and 2). Decreased transfer of human LDL into the aorta in SR-B1 ΔEC mice was confirmed by quantification in aorta homogenates (Extended Data Figs. 3j, k, 4j, k, 6d, e, j, k), and uptake of mouse LDL and intermediate or very-lowdensity lipoproteins (IDL/VLDL) was also decreased (Extended Data Fig. 3l, m) . The previous finding that there is less LDL accumulation in ex vivo perfused arteries from global SR-B1 −/− mice 10 is likely to have been related to loss of the receptor in the endothelium. In SR-B1 ΔEC mice, uptake of Evans blue dye in the aorta was unaltered (Fig. 1m) , and in mice with intact endothelial SR-B1, treatment with an anti-SR-B1 blocking antibody lowered the incorporation of LDL into the aorta (Extended Data Fig. 6f , g, l, m), and LDL and SR-B1 were colocalized in intracellular vesicles in endothelial cells (Fig. 1n , Extended Data Fig. 7) . Moreover, whereas fluorescence-activated cell sorting studies of CD45 +
F4/80
+ macrophages indicated that their numbers were unchanged in the artery walls of SR-B1 ΔEC mice, fewer macrophages contained administered LDL in these mice (Fig. 1o , p, Extended Data Figs. 5l, 6h, i). These observations indicate that endothelial SR-B1 mediates the transcellular transport of LDL from the circulation into Letter reSeArCH the artery wall and the formation of foam cells, thereby promoting atherosclerosis.
We next investigated the relative importance of and mechanistic basis for trafficking of LDL by SR-B1 in human aortic endothelial cells (HAECs). Regarding the initial step in LDL transport, whereas knockdown of SR-B1 decreased uptake of DiI-LDL, ablation of PDZK1 had no effect (Extended Data Fig. 8a ), as previously observed with HDL 13 . The anti-SR-B1 blocking antibody and the chemical SR-B1 inhibitor BLT-1 also attenuated LDL uptake, and either treatment or knockdown of SR-B1 blunted transcytosis of LDL across endothelial cell monolayers (Extended Data Fig. 8b-d) . We investigated whether the loss of SR-B1 impairs the function of endothelial cell caveolae, which mediate LDL transport 14, 15 , in studies of ligand-induced eNOS activation. Whereas SR-B1 silencing predictably negated HDL-mediated activation of eNOS 6 , stimulation by the eNOS agonist VEGF was unaffected (Extended Data Fig. 8e ), paralleling the finding that whereas there is a complete loss of HDL-induced vasodilation in aortic rings from SR-B1 −/− mice, acetylcholine-induced vasodilation is normal 6 . By contrast, disruption of caveolae structure by cyclodextrin blunted the activation of eNOS by both VEGF and HDL (Extended Data Fig. 8f) . Thus, the attenuation of LDL transport observed with the loss of SR-B1 from endothelial cells is not related to an alteration in the caveolae microenvironment.
We also investigated the capacity of other endothelial receptors for LDL to mediate transport of the lipoprotein [16] [17] [18] . Whereas knockdown of LOX-1 (also known as Olr1) did not alter uptake of nLDL or oxLDL by HAECs (data not shown), RNA interference (RNAi)-mediated silencing of the LDL receptor (Ldlr) or Cd36 attenuated uptake, and blocking antibodies had a similar effect; however, neither LDLR nor CD36 antibody blockade altered transcytosis of nLDL or oxLDL (Extended Data Fig. 8g-m) . Thus, among classical lipoprotein receptors, whereas LDLR, CD36 and SR-B1 all promote LDL uptake by human endothelial cells, only SR-B1 drives LDL transcytosis.
We next compared the capacity for endothelial LDL transcytosis by SR-B1 and activin receptor-like kinase 1 (ALK1), to which LDL binding and transport has been previously ascribed 19 . LDL transcytosis was decreased to a similar degree by the selective loss of SR-B1 or Alk1 (also known as Acvrl1), and there was a further decline with their concurrent knockdown (Extended Data Fig. 9a-f) . Thus, both SR-B1 and ALK1 mediate LDL transcytosis in endothelial cells, and they are likely to do so by different mechanisms. Notably, endothelial expression of ALK1 was normal in SR-B1 ΔEC mice (Extended Data Fig. 1f ), so the in vivo findings relating endothelial SR-B1, LDL delivery to arteries, uptake of LDL by macrophages and atherosclerosis can be attributed specifically to SR-B1.
We then determined whether binding of LDL to SR-B1 is required for LDL to be trafficked across the endothelium. Endogenous SR-B1 was silenced in HAECs, and its expression was reconstituted using wild-type SR-B1 or five forms of point mutant previously (M159E and T165E) 20 or newly (F171A, T175A, and E178A) shown to have attenuated LDL binding (Fig. 2a, Extended Data Fig. 10a-c) . We also tested another point mutant, Q445A, which has normal LDL binding (Extended Data Fig. 10c ) but disrupted interactions between SR-B1 and plasma membrane cholesterol 21 . Whereas reintroduction of wild-type SR-B1 yielded uptake of nLDL and oxLDL comparable to that seen with endogenous SR-B1, cells expressing SR-B1 with decreased LDL binding had markedly diminished LDL uptake; by contrast, cells with the Q445A mutant showed normal LDL uptake (Fig. 2b) . The majority of LDL transcytosis by SR-B1 was also attenuated if LDL binding was diminished (Fig. 2c) . Thus, direct association is essential for trafficking of LDL by SR-B1 in endothelial cells.
Because SR-B1 lacks the internalization sequence Tyr-X-X-θ (where X is any amino acid and θ is a bulky hydrophobic amino acid) that is characteristic of other LDL receptors 22 , we hypothesized that SR-B1 has an associated partner protein(s) that is required for its internalization and endothelial transcytosis of LDL. As a first test, we generated deletion mutants lacking the C-terminal 15, 23 or 30 residues of 100 nm 100 nm a b Letter reSeArCH SR-B1, designated ∆C15 (∆495-509), ∆C23 (∆487-509) and ∆C30 (∆480-509) (Fig. 2a, Extended Data Fig. 10d-f) . Whereas in cells expressing SR-B1(∆C15), LDL uptake and transcytosis were comparable to cells expressing full-length wild-type SR-B1, both processes were attenuated in cells expressing SR-B1(∆C23) or SR-B1(∆C30) (Fig. 2d, e) . These findings suggested that residues 487-494 (IQAYSESL; Fig. 2a ), which are highly conserved in SR-B1 and unique to SR-B1 compared to CD36 (Extended Data Fig. 10g ), are required for these processes. To test this possibility, we replaced the first four (IQAY) or last four (SESL) residues with alanines, or made single alanine substitutions (Fig. 2a, Extended Data Fig. 10h-j) . Cells expressing the IQAY or SESL mutant, or SR-B1(Y490A) or SR-B1(S491A), showed markedly reduced uptake and transcytosis of nLDL and oxLDL (Fig. 2f, g ); cells expressing SR-B1(Q488A) had attenuated uptake and transcytosis of nLDL. When we tested various receptor mutants, we confirmed these findings for binding, uptake and transcytosis of nLDL at concentrations that saturate LDLR binding (100 μg ml -1 ), and found that the abundance of endogenous CD36 and LDLR was unaltered (Extended Data Fig. 10k-n) . Thus, amino acids 487-494 (IQAYSESL) in the C-terminal cytoplasmic tail of SR-B1 are critical for uptake and transcytosis of LDL by endothelial cells.
Next we tested the hypothesis that residues 487-494 of SR-B1 are required for the interaction of SR-B1 with a cytoplasmic protein(s) that is necessary for LDL transport. We evaluated the interactomes of N-terminally His-tagged SR-B1 or SR-B1(ΔC23) in HAECs using liquid chromatography and tandem mass spectrometry (LC-MS/ MS). One of the 33 proteins that showed a stronger interaction with His-SR-B1 than with His-SR-B1(ΔC23) was DOCK4, which is a membrane-associated cytoplasmic protein that functions as a guanine nucleotide exchange factor (GEF) and participates in regulation of the actin cytoskeleton 4, 23, 24 . Co-immunoprecipitation experiments in HAECs confirmed that DOCK4 interacts with amino acids 487-494 of SR-B1 (Fig. 3a, b) , and nLDL and oxLDL caused similar increases of 72-94% in SR-B1-DOCK4 coupling (Fig. 3c) . We found coexpression of SR-B1 and DOCK4 in aortic endothelium in vivo (Fig. 3d) , and compared with the atherosclerosis-resistant greater curvature of the aortic arch, mRNA levels of both SR-B1 and Dock4 were increased in the atherosclerosis-prone lesser curvature before lesion formation (Fig. 3e, f) . Furthermore, in three independent, publicly available patient cohorts, expression of both SR-B1 and DOCK4 was greater in atherosclerotic arteries than normal arteries (Fig. 3g-l) .
As DOCK4 mediates internalization of platelet-derived growth factor (PDGF) receptors in fibroblasts 24 , we investigated whether SR-B1 is internalized in HAECs and, if so, whether DOCK4 is required. Upon the resumption of endocytosis with warming from 4 °C to 37 °C in the presence of nLDL or oxLDL, cells expressing DOCK4 showed internalization of cell-surface biotin-labelled SR-B1, and knockdown of Dock4 attenuated this internalization (Fig. 4a, b) . By contrast, internalization interaction (% cont.) P < 0.0001 Data are expressed relative to values for greater curvature, with mean value for greater curvature designated to equal 1.0. g-l, We used three patient cohorts and independent strategies for analyses to compare expression of SR-B1 (g-i) and DOCK4 (j-l) between human atherosclerotic (Athero.) and control arteries. Cohorts I, II and III contained n = 4 and 207, 40 and 40, and 32 and 32 subjects, respectively. FPKM, fragments per kilobase of transcript per million mapped reads. Data are mean ± s.e.m.; in d and f, P values calculated by two-sided Student's t-test; in g-l, data are presented as box-and-whisker plots (central lines, medians; box edges, upper and lower quartiles; whiskers, minimum and maximum values after excluding outliers outside 1.5× the interquartile range). Letter reSeArCH that both SR-B1 and DOCK4 were required for transcytosis of LDL (Extended Data Fig. 9k, l) . By contrast, whereas transcytosis of HDL was decreased by SR-B1 silencing (as previously shown) 13 , knockdown of Dock4 had no effect (Fig. 4g) , indicating that the involvement of DOCK4 in SR-B1-mediated transport of lipoproteins in endothelial cells is cargo-specific. As DOCK4 is a GEF for the RHO GTPase RAC1 4 , we investigated the involvement of RAC1 in LDL trafficking. Treatment with LDL caused activation of RAC1, and this was prevented by silencing either SR-B1 or Dock4 (Fig. 4h, i) ; attenuation of the activation of RAC1 (Extended Data Fig. 9m ) blunted uptake of LDL by SR-B1 (Fig. 4j) . Thus, through a dynamic partnership with DOCK4 serving as a GEF for RAC1, SR-B1 mediates transcytosis of LDL in endothelial cells to deliver circulating LDL into the subendothelial space, where it is engulfed by macrophages that become foam cells and promote the formation of atherosclerotic lesions (Fig. 4k) .
It has long been believed that the delivery of circulating LDL into the artery wall, which instigates atherosclerosis, entails its passive movement through a compromised endothelial barrier at lesion-prone sites, which display higher rates of endothelial senescence and apoptosis, and reduced proliferative reserve and repair capacity [25] [26] [27] . We have shown that active transcellular transport of LDL by SR-B1 in the endothelium drives atherogenesis. This mechanistic understanding of disease-promoting entry of LDL into the artery wall might allow the development of interventions that inhibit this process, representing a new therapeutic category in the battle against cardiovascular disease.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Animal models. Experiments were performed in male and female wild-type, ∆EC mice for studies of receptor loss-of-function in the endothelium contrasts with previous gain-of-function studies performed in mice harbouring a Tie2-driven SR-B1 transgene 28 . In that work, overexpression of SR-B1 yielded atheroprotection. However, the transgene caused a decline in plasma cholesterol and a 50% increase in HDL, and since Tie2-driven gene expression occurs in haematopoietic lineages and endothelium 29 , non-endothelial processes cannot be excluded. We also crossed SR-B1
∆EC mice with Alb-Cre mice (B6.Cg-Tg(Alb-Cre)21Mgn/J, Jackson Laboratory) 30 to generate mice deficient in SR-B1 in hepatocytes, designated SR-B1 genome copies (gc) per mouse). All mice were maintained on standard chow. In studies of atherosclerosis, beginning at weaning at age 4 weeks, Apoe −/− mice were fed an atherogenetic diet (D12108C, 20% fat, 1.25% cholesterol, Research Diets Inc.) for 8 weeks, Ldlr −/− mice were fed TD96335 (6.2% fat, 1.25% cholesterol, Harlan Laboratories) for 12 weeks, or following AAV8-PCSK9 injection at 4-5 weeks of age, mice were fed TD96335 for up to 12 weeks. All animal experiments were approved by the Institutional Animal Care and Use Committee at UT Southwestern. Atherosclerosis evaluation and lipid analyses. Atherosclerotic lesions were evaluated as previously described 33 . Mice were anaesthetized with isoflurane, blood was collected for lipid analyses, and the vascular system was perfused with normal saline administered by left ventricle puncture. Adventitial fat was removed from the aortic arch before in situ imaging. The heart and whole aorta were isolated and placed in 10% formalin for fixation overnight, the heart was dehydrated in 30% sucrose at 4 °C overnight and embedded in OCT compound (Fisher Healthcare), and serial frozen sections (8 μm) of the aortic root were obtained. Ten to fifteen slides with six sequential sections each were prepared from each heart, and 1-2 slides per heart were processed for Oil Red O staining of the aortic sinus. For en face analysis, the entire aorta from the aorta root through the bifurcation of the iliac arteries was stained with Oil Red O for 2 h at room temperature, adjoining tissues were removed, and the aorta was opened longitudinally and pinned onto a black silicon bed. Lesions were quantified by morphometry of obtained images using Photoshop software.
Plasma total cholesterol and triglyceride concentrations were determined by colorimetric enzymatic assay (Infinity, Thermo Scientific). HDL levels were determined by precipitating apoB-containing lipoproteins using phosphotungstate-magnesium and measurement using the HDL Cholesterol Kit (Wako) 34 . Plasma lipid profiles were obtained by column fractionation and measurements of fraction cholesterol content 35 . Cardiac phenotyping. Using previously described methods 8 , hearts were excised and rinsed in PBS and fixed in 10% formalin for 48 h, embedded in paraffin, and sectioned at 5-μm intervals. Haematoxylin and eosin staining and Masson's trichrome staining were performed following standard procedures. Macrophage content was evaluated by immunohistochemistry using anti-CD68 antibody (ab955, Abcam). Survival curves were generated to compare the overall outcome of SR-B1 fl/fl control mice and SR-B1 ΔHEP mice that were made hypercholesterolaemic with AAV8-PCSK9. In vivo leukocyte-endothelial adhesion and endothelial permeability. Leukocyte-endothelial adhesion was assessed using our previously established method 35 . In brief, in 4-5-week-old male mice, endogenous leukocytes were fluorescence labelled by injection with 100 μl rhodamine-6G (0.05% w/v) via the optic vascular plexus. Under anaesthesia, the mesentery was exposed on a clear dish for observation and recording of images of leukocyte adhesion and rolling in the mesenteric microvasculature using a Regita digital camera (400× magnification; QImaging). The velocity of leukocyte rolling was calculated using Image-Pro V.6.2 (Media Cybernetics). To evaluate adhesion under both control and proinflammatory conditions, mice received an intraperitoneal injection of normal saline or TNF (0.3 μg per mouse) 4 h before study.
To evaluate endothelial permeability, mice were injected retro-orbitally with 0.5% (w/v) Evans blue dye dissolved in normal saline (4 μl per g body weight) as described previously 36 . After 1 h, the mice were euthanized and perfused via the left ventricle with 10 ml cold PBS. The entire aorta was isolated, washed in PBS, and placed in formamide at 55 °C for 48 h. Following centrifugation, the dye concentration was determined by measuring absorbance at 650 nm with comparison to a standard curve. In vivo aorta LDL uptake. Human native LDL (nLDL) was provided by J. Goldstein and M. Brown (UT Southwestern). In brief, LDL particles were isolated by ultracentrifugation from normal human plasma and stored in buffer containing 0.27 mM EDTA at 4 °C. To generate oxidized LDL (oxLDL), nLDL particles at a concentration of 1 mg protein per ml were incubated with 5 μM CuSO 4 at 37 °C for 24 h, 100 μM EDTA and 20 μM butylated hydroxytoluene were added to terminate oxidation, and the resulting samples were dialysed with PBS for 48 h. Mouse LDL (density 1.019-1.063 g/ml) and VLDL/IDL (density 1.006-1.019 g/ml) were obtained from pooled LDLR −/− mouse plasma by sequential ultracentrigation 37 . To optimize their detection, nLDL, oxLDL or mouse LDL or VLDL/IDL were labelled with 1,1′diocta-decyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI, Invitrogen) at 37 °C for 16 h, centrifuged at 16,000g for 10 min at 4 °C, and dialysed with PBS for 24 h. DiI-labelled LDL was stored at 4 °C and used within 1-2 weeks 38 .
To evaluate uptake of LDL in the aorta in vivo, following receipt of an atherogenic diet for one week, 8-10-week-old mice were injected retro-orbitally with 100 μg DiI-LDL, and 0-4 h later the mice were anaesthetized and perfused with ice-cold PBS for 5 min, and the thoracic aorta was isolated. Following removal of the adventitia, the aorta was digested in RIPA buffer (Thermo Fisher) containing protease inhibitor cocktail (P8340, Sigma), and DiI-labelled lipoprotein content was quantified either using a fluorometer (POLARstar Omega, BMG LABTECH) and measurement of aorta homogenate protein content (Pierce BCA Protein Assay Kit), or, when human LDL was used, by immunoblotting with anti-human apoB antibody (MA5-15851, ThermoFisher) and anti-calnexin antibody (ADI-SPA-860-F, Enzo Life Sciences) to assess protein loading. To test the impact of a pharmacologic intervention that targeted SR-B1, in some experiments the mice received either control sera or SR-B1 blocking antibody (1:2 dilution, 200 μl) 39 both16 h and 1 h before the administration of DiI-LDL.
To visualize LDL transport across the endothelial monolayer in vivo, 4 h after intravenous DiI-LDL administration the aorta was isolated, subjected to Hoechst staining (5 μg/ml) at 4 °C for 30 min to identify nuclei and washed three times, and then confocal fluorescence microscopy was performed on the luminal surface using a 20× objective and a Zeiss LSM710 NLO two-photon excitation microscope. The methods were adapted from approaches used to image the brain vasculature of mice 40 . A minimum of three randomly selected regions in the ascending aorta were imaged per mouse to a depth of approximately 50 μm (Z = 1-2 μm), and the data obtained were analysed using Zeiss ZEN software.
To quantify LDL uptake by artery wall macrophages or foam cells, 4 h after intravenous DiI-LDL administration, CD45 + F4/80 + cells were isolated from the aorta using our established approach 41 . The aorta was digested with liberase TH (4 U/ml, Roche), DNase (DNase) I (0.1 mg/ml, Sigma), and hyaluronidase (60 U/ml, Sigma) at 37 °C for 2 h, and flow cytometry (BD Biosciences LSR II) was performed with 1:200 dilutions of anti-CD45 (clone 30-F11) and anti-F4/80 (clone BM8) antibodies (Biolegend) as well as detection of DiI signal. The data obtained were analysed using FlowJo software (Treestar). Electron microscopy. The subcellular localization of intravascularly administered LDL particles and SR-B1 in aortic endothelial cells was evaluated by electron microscopy (EM). Following fasting for 4 h, 10-week-old C57BL/6 mice were anaesthetized and the aorta was cleared of blood in situ by perfusion with PBS with 0.25% glucose at 37 °C. The thoracic aorta was then perfused (15 ml/min) with colloidal gold-labelled nLDL (10-15 nm diameter, 50 μg/ml in EBM2 medium plus 1% BSA, 37 °C) 42, 43 from proximal to distal, and the perfusate was recirculated. Ten minutes later the thoracic aorta was washed with ice-cold PBS (10 ml) to remove unbound LDL, removed and opened longitudinally, and incubated in EM fixation solution (4% PFA in 0.1 M phosphate buffer pH 7.4, containing 0.1% glutaraldehyde) for 30 min at room temperature. SR-B1 was visualized using a primary antibody against mouse SR-B1 (Novus, NB400-104) 44 and a fluoronanogold (1.4-nm diameter)-conjugated secondary antibody (Alexa Fluor 488-FluoroNanogold Fab goat anti-rabbit IgG, 7204, Nanoprobes). The immunogold-labelled samples were further gold-enhanced for 2.5 min using a gold enhancement kit (Nanoprobes). After washing with water and 0.1 M cacodylate buffer, samples were fixed with 1% OsO 4 and 0.8% potassium ferricyanide in 0.1 M cacodylate buffer for 1 h, stained en bloc with 2% aqueous uranyl acetate, dehydrated with increasing concentrations of ethanol, and embedded in Epon. Blocks were sectioned with a diamond knife (Diatome) on a Leica Ultracut 7 ultramicrotome (Leica Microsystems) and collected onto copper grids. Images were acquired on a JOEL 1400 Plus transmission electron microscope equipped with a LaB6 source using a voltage of 120 kV, and the images were captured using an AMT BIOSPRINT 16M-ActiveVu mid mound CCD camera. In sections processed in the absence of primary anti-SR-B1 antibody, the gold particles detecting SR-B1 were absent. Cultured cell models, gene silencing and reconstitution. Primary HAECs (Lonza) were maintained in EBM2 medium with 10% (v/v) fetal bovine serum and studied at passages 3-6. Gene silencing was accomplished using predesigned and validated siRNAs targeting SR-B1 (s2648), Pdzk1 (s10282), Lox1 (s9842), Ldlr (S224006), or Cd36 (s534752) (Life Technologies Corp.), and effective knockdown was confirmed by immunoblot analysis. Alk1 was silenced using shRNA (TRCN0000000354) (Sigma), and successful loss of Alk1 was confirmed by qRT-PCR and measurement of Ser463/465 phosphorylation of SMAD1/5 in response to BMP9 treatment (10 ng/ml) for 0-120 min 19 . In studies of DOCK4, gene silencing was done with a lentiviral shuttle plasmid for shRNA targeting human DOCK4 (TRCN0000288692) (Sigma). In some studies, including the experiments determining the structural features of SR-B1 required for LDL transport, the endogenous receptor was knocked down by shRNA targeting the 3′UTR of the human SR-B1 gene (5′-C CG GGCTCGTCAACAAGCACTGTTCCTCGA GGAACAGTGCTTGTTGACGAGCTTTTTG-3′ in pLKO.1-TRC). Wild-type or mutant forms of SR-B1 were reintroduced using CMV promoter-driven lentiviral constructs. Polybrene (8 μg/ml, EMD Millipore) was added to the medium to enhance lentiviral transduction efficiency, and experiments were performed 48 h later. The SR-B1 mutants were generated using cDNA encoding human SR-B1 (NM_005505, Sino Biological Inc.) and the Virapower Lentiviral Expression System (ThermoFisher). Shuttle plasmid (5 μg), psPAX2 packaging plasmid (3 μg), and pMD2.G envelope plasmid (2 μg) were co-transfected into HEK-293FT cells in DMEM using Fugene6. Six hours and 48 h post-transfection, the medium was replaced with DMEM containing 2 mM caffeine and 30% FBS. The lentiviral particles were harvested 48 h and 72 h after transfection, passed through a 0.45-μm filter (Millipore) to remove cellular debris, concentrated by ultracentrifugation at 100,000g for 90 min at 4 °C, and resuspended in Dubelcco's phosphate-buffered saline (Gibco) overnight at 4 °C. The lentiviral preparations were then aliquotted and stored at -80 °C, and SR-B1 mutations were confirmed by sequencing.
Total cell abundance of the reconstituted wild-type or mutant forms of SR-B1 was evaluated by immunoblot analysis 48 h after lentiviral transduction. To assess cell surface abundance, cells were incubated with anti-SR-B1 antibody directed against the extracellular domain (NB400-134, Novus Biologicals) on ice for 30 min, washed three times, incubated with Alexa488-conjugated secondary antibody for 30 min at 4 °C, washed three times, and subjected to flow cytometry (BD Biosciences LSR II). Quantitative RT-PCR. Transcript abundance was evaluated in mouse aorta, mouse aortic endothelial cells or human endothelial cells by qRT-PCR using previously established methods 35 . Binding, uptake and transcytosis of LDL. To evaluate DiI-LDL binding, cells in 24-well plates were precooled at 4 °C for 10 min, incubated with 50 ug/ml DiI-LDL at 4 °C for 10 min, washed three times with ice-cold PBS and lysed in 1% Triton X100 at room temperature for 10 min with shaking, and fluorescence was quantified using a fluorometer (POLARstar Omega, BMG LABTECH) and normalized to total protein content.
LDL uptake studies entailed cell incubation with 10 μg/ml DiI-LDL for 4 h at 37 °C. In select experiments, the DiI-LDL incubation followed a 1-h preincubation with DMSO control vehicle versus the SR-B1 inhibitor BLT-1 (10 μM, Sigma) 45 , or control unrelated IgG versus anti-SR-B1 blocking antibody. DMSO control had no effect on LDL transport. Cells were washed with PBS and lysed for the measurement of fluorescence intensity using a fluorometer. For imaging of LDL uptake, experiments were performed with cells seeded onto glass coverslips precoated with collagen I. Following incubation with DiI-LDL, cells were fixed with 1% formalin in PBS for 10 min at room temperature, nuclei were stained with DAPI, mounting medium was added (Vector Laboratories, Inc.), and fluorescence microscopy was performed at 40× magnification with a Nikon Eclipse TE2000-E microscope.
Transcytosis of LDL was studied using approaches derived from previously reported methods 32 . Cells were seeded twice, 24 h apart, onto 0.4-μm pore PET Transwell inserts (3610, Corning, Inc.) coated with collagen I (BD Bioscience), with or without lentiviral transduction overnight. Transcytosis was evaluated 48 h later, at which time measurements of transepithelial electrical resistance using an epithelial volt-ohmmeter (World Precision Instruments) confirmed the establishment of a confluent monolayer. Fluorescein isothiocyanate (FITC)-dextran (molecular weight, 3,000; Invitrogen) was used to assess paracellular transport. Cells were incubated simultaneously for 2 h with FITC-dextran and 50 μg/ml DiI-LDL added to the upper chamber, and the fluorescence intensity of FITC and DiI in the lower chamber was measured using a fluorometer (POLARstar Omega, BMG LABTECH). FITC-dextran transport was 2-3%, and similar for control cells and cells in which SR-B1 expression was reconstituted. Infrequently observed inserts displaying paracellular transport more than 5% were discarded. The addition of 50-fold excess LDL decreased the DiI signal for transcytosis by 75%. In select experiments, interventions were placed in the upper chamber for 1 h before the addition of DiI-LDL. Under control conditions the per cent transcytosis of DiI-LDL was approximately 12%, and the data shown are normalized to control values. HDL transcytosis was also performed using DiI-labelled lipoprotein. The validity of the uptake and transcytosis assays using DiI-LDL was confirmed using nLDL labelled with iodine-125 by the Bolton-Hunter method. In uptake studies, cells were incubated with 10 μg/ml 125 I-LDL for 4 h, washed with PBS and lysed with 0.1 N NaOH, and radioactivity was quantified in the cell lysate using a Wizard Automatic Gamma Counter (PerkinElmer) and expressed relative to protein content. For transcytosis studies, cells were incubated with 50 μg/ml 125 I-LDL for 2 h and radioactivity in both the upper and lower chambers was quantified.
To provide an additional means to confirm the findings obtained for transcytosis, TIRF microscopy was used 10, 19 . Time-lapse imaging of transcytosis was carried out on an OMX SR microscope in Ring TIRF mode (GE Healthcare Life Science). In brief, endothelial cells seeded in 35-mm glass-bottom dishes (MatTek, MA) were treated with 50 μg/ml DiI-nLDL in EGM2 medium with HEPES at 4 °C for 10 min to allow the LDL to bind to the apical cell surface without internalization. Endothelial cells pretreated with Dyngo4A (30 μM; Abcam) for 30 min were processed in parallel to confirm the dynamin dependence of transcytotic events 10 . The cells were rinsed with cold PBS, warm medium was added, and the dish was placed in a 37 °C live cell incubation chamber on the microscope stage for 2 min before imaging. An Olympus ApoN 60× 1.49 NA lens was used for through-the-objective TIRF with 561-nm laser excitation. The TIRF angle was set at 96% of the back aperture of the lens, for an estimated nominal penetration depth of 70 nm. Images were acquired using a cooled sCMOS camera with a 50-ms exposure at 150-ms intervals for a minimum of 40 s. At least 15 randomly selected cells were imaged for each condition, and the transcytosis events in the first 5-6 cells imaged were quantified using Imaris 9.2.0. image analysis software (Bitplane, Zurich Switzerland). Spots Wizard was used to identify DiI-labelled LDL particles and track them over time. The spots were filtered on the basis of mean squared displacement over time to exclude those exhibiting Brownian motion or active transport, and statistics measured by Imaris were exported for analysis in Excel. Numbers of transcytosis events captured in 200 frames were determined using criteria reported previously 19 . NOS assays. To assess caveolae function in cultured endothelial cells, the conversion of 14 C-l-arginine to 14 C-l-citrulline was measured in intact cells under basal conditions or with the addition of VEGF (100 ng/ml) or HDL (20 μg/ ml) 46 . In select studies, caveolae were disrupted by cell treatment with methyl-β-cyclodextrin (10 mM for 60 min) before the evaluation of NOS activation. LC-MS/MS. To identify proteins that interacted with SR-B1 in endothelial cells, SR-B1 immunoprecipitation was facilitated by N-terminal His tagging of the receptor. N-terminal tagging was chosen because the SR-B1 N-terminal tail does not participate in any known function of the receptor 47 , and the addition of the N-terminal His tag did not affect LDL uptake by SR-B1 in HAECs (data not shown). An N-terminal His tag was also placed on the SR-B1(ΔC23) truncated form of the receptor. Endogenous SR-B1 was silenced in HAECs, receptor expression was reconstituted with either His-SR-B1 or His-SR-B1(ΔC23), SR-B1 was immunoprecipitated with anti-His antibody, and the associated proteins were evaluated by LC-MS/MS. Immunoprecipitated protein samples were electroporated 10 mm into the top of a pre-cast SDS-PAGE gel (Bio-Rad), stained with Coomassie blue and excised. Following alkylation and reduction with dithiothreitol and iodoacetamide (Sigma), samples were digested overnight with trypsin (Promega) and then subjected to LC-MS/MS using a QExactive mass spectrometer (Thermo Electron) coupled to an Ultimate 3000 RSLC-Nano liquid chromatography system (Dionex). Peptides were loaded onto a 180-μm i.d., 5-cm-long, self-packed column containing 1.9 μm C18 resin (Dr. Maisch, Ammerbuch, Germany) and eluted with a gradient of 0-40% buffer containing 80% (v/v) ACN, 10% (v/v) trifluoroethanol, and 0.08% formic acid for 60 min. Up to 10 high-energy, collision-induced dissociation fragment spectra were obtained for each full spectrum acquired. Raw MS data files were converted to peak list format using ProteoWizard Msconvert, and the resulting files were analysed using the Central Proteomics Facilities Pipeline 48 .
Label-free quantification of proteins across samples was performed using the Normalized Spectral Index method (SINQ) 49 .
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Co-immunoprecipitation and immunoblot analyses. Co-immunoprecipitation studies were performed to evaluate proteins that interacted with either His-tagged wild-type or mutant SR-B1, or DOCK4, in HAECs. Cells were incubated with lysis buffer containing 25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 5% glycerol (Thermo Fisher) supplemented with protease inhibitor cocktail (P8340, Sigma) on ice for 1 h with vortexing every 20 min. Supernatants collected following centrifugation at 14,000g at 4 °C for 10 min were incubated with control IgG, anti-DOCK4 (ab85723, Abcam) or anti-His (ab18184, Abcam) antibodies at 4 °C overnight, and protein A/G plus agarose beads (Pierce) were added for 2 h. The beads were pelleted by centrifugation, washed three times, and the bound proteins were eluted with SDS sample buffer and analysed by SDS-PAGE and immunoblotting. Primary antibodies used were anti-DOCK4 antibody and anti-SR-B1 antibody recognizing the N terminus (ab52629, Abcam) to identify C-terminally truncated SR-B1. HRP-conjugated secondary antibodies and chemiluminescent detection and densitometry were then used.
In cell culture experiments, additional immunoblot analyses were performed using anti-SR-B1 (NB400-113 and NB400-134, Novus; ab52629, Abcam), anti-PDZK1 (ab64856, Abcam), anti-LOX-1(MAB1798, R&D Systems), anti-LDLR (AF2148, R&D Systems), anti-CD36 (NB400-144,Novus; MA-5-14112, Invitrogen) and anti-transferrin receptor (ab84036, Abcam) antibodies. Protein loading was assessed using anti-GAPDH (sc-365062, Santa Cruz) antibody. Gene expression profiling in human atherosclerotic versus normal arteries. To compare SR-B1 and DOCK4 in human atherosclerotic versus normal arteries, three publicly available independent human atherosclerosis cohorts with gene expression data were downloaded from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). The accession numbers were GSE116243, GSE40231, and GSE43292. For the GSE116243 cohort (Cohort I), which included atherosclerotic aortic lesions, the gene expression profiling was generated by RNA sequencing through Illumina HiSeq 2500. For comparison, RNA sequencing datasets of aortas from healthy donors were downloaded from the Genotype-Tissue Expression (GTEx) database (https://gtexportal.org/home/) with accession number phs000424.v6.p1. RNA sequencing reads from FASTQ files were quality-filtered using FASTQ Quality Filter (-q 20 -p 75) from the FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). The filtered reads were then aligned to the hg38 reference genome by HISAT2 aligner 50 . Cufflinks 51 was used to assemble and estimate the relative abundances of transcripts at the gene and transcript levels. For the GSE40231 cohort (Cohort II), which compared atherosclerotic aortic lesions with internal mammary artery from the same subjects, gene expression profiling was generated using the Affymetrix Human Genome U133 Plus 2.0 Array. Signal intensity CEL files were downloaded from GEO and then processed using Affymetrix Power Tools (APT) with Robust Multiarray Average (RMA) method. For the GSE43292 cohort (Cohort III), which matched atherosclerotic carotid artery with healthy carotid artery from the same subject, gene expression profiling was generated using the Affymetrix Human Gene 1.0 ST Array. CELL files were downloaded from GEO and then analysed using R/BioConductor package with RMA method and custom PERL scripts. Data are presented as box-and-whisker plots, with the central lines denoting medians, edges of the box representing upper and lower quartiles, and whiskers showing minimum and maximum values after excluding outliers outside 1.5× the interquartile range. Notably, although the analyses of the three cohorts used different technology platforms to measure gene expression, the same findings were obtained. Internalization of SR-B1. To evaluate internalization of SR-B1, following surface protein labelling with 2 mM sulfo-NHS-SS-biotin at 4 °C for 30 min 33 , cells were washed with 100 mM glycine in PBS to quench non-reacted biotinylation reagent, and then incubated with 50 μg/ml DiI-LDL at 37 °C for 0-10 min. The remaining cell surface biotin was cleaved with 50 mM reduced glutathione (Sigma), cells were lysed in RIPA buffer, biotinylated proteins were isolated by incubating with streptavidin magnetic beads overnight at 4 °C, the bound proteins were eluted with loading buffer, and immunoblot analysis was performed. To assess the efficacy of SR-B1 biotinylation, whole cell lysates were obtained after 0-10 min of incubation, and total biotinylated SR-B1 was quantified by immunoblotting. To evaluate the internalization of another cell surface protein, the abundance of internalized transferrin receptor and total biotinylated transferrin receptor were determined in a parallel manner. RAC1 activity assay and RAC1 loss of function. RAC1 activity was evaluated by affinity purification and immunoblotting (Millipore). Following cell treatment, cell lysates were incubated with PAK1 PBD agarose to bind activated, GTPbound RAC1, and its abundance was determined by immunoblotting. Total RAC1 in cell lysates was also evaluated by immunoblotting. To determine the role of RAC1 in uptake of LDL by endothelial cells, cells were transduced with adenovirus encoding GFP or a dominant-negative form of RAC1 (T17N) 52 with MOI 100 for 48 h before the uptake assay. The effect of pharmacologic inhibition was also tested by pretreating cells with vehicle or the RAC1 inhibitor NSC23766 (100 μM) 53 for 1 h before the uptake assay.
Statistics and reproducibility. Results are expressed as mean ± s.e.m. Comparisons between two groups were done by two-sided Student's t-test unless otherwise noted, and analysis of variance (ANOVA) with Dunnett's post-hoc testing was performed to compare three or more groups. P < 0.05 was considered statistically significant. When representative findings are presented, similar results were obtained at least three times. Observations in cell culture were confirmed in three independent experiments. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All figures have associated raw data, which are available with permission from the corresponding author.
1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Flow cytometry data analysis was performed using FlowJo software (Treestar), confocal microscopy data analysis using ZEN Black Edition software, and leukocyte adhesion and rolling data analysis using Image-Pro v.6.2 (Media Cybernetics). All other data analyses were performed using Graphpad Prism vers. 7.03.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
When evaluating changes in atherosclerotic lesion development with the manipulation of SR-B1 in apoE null mice, we observed a difference in percent lesion area of 8.7%, with a standard deviation of 5.7%. Using these values and a Type I error of 5% and a Type II error of 10%, the number of mice needed per group is 9. No power calculations were performed for the other types of experiments pursued. Sample sizes were chosen based on standard practice for that type of experiment. For studies performed in mice, the number of independent mice employed is either apparent in the data or listed in the figure legend.
Data exclusions No data were excluded for data analysis.
Replication
Findings in in vivo mouse studies were replicated in 2-3 separate cohorts. Findings from cell culture studies were replicated at least 3 independent experiments.
Randomization Within all genotype groups, age-and sex-matched animals were randomly assigned to the experimental groups.
Blinding
The investigators were not blinded to experimental group assignment.
Reporting for specific materials, systems and methods 
Validation
In addition to the validation provided by the commercial sources, we independently validated the specificity of the antibodies
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used in western blotting by RNAi deletion of the protein being detected. For immunofluorescence, we validated the specificity by performing control studies omitting the primary antibody or deleting the antigen protein by shRNA. 
Wild animals
Wild animals were not used.
Field-collected samples
Field-collected samples were not used.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
In the studies of aorta macrophages, the aortas were digested with liberase TH (4 U/ml,Roche), deoxyribonuclease (DNase) I (0.1 mg/ml, Sigma), and hyaluronidase (60 U/ml, Sigma) at 37C for 2h. In the studies of human aortic endothelial cells expressing reconstituted wild-type SR-B1 or mutant forms of SR-B1, cells were fixed in formalin and then incubated with primary and secondary antibodies on ice. Cell population abundance Abundance of aorta CD45+,F4/80+ macrophages was approximately 20,000.
Gating strategy
Compensation was performed with single antibody-stained cells. Unstained cells were used as gating controls. All cells were first gated in FSC/SSC according to cell size and granularity. The resulting population (100,000 events) was then gated according to cell viability using DAPI (Sigma). Subsequently the cells were gated according to positivity or negativity for the specific surface markers being interrogated.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
